



Phenotypic and Genotypic Characterization of a Hypervirulent Carbapenem-Resistant *Klebsiella pneumoniae* ST17-KL38 Clinical Isolate Harboring the Carbapenemase IMP-4

Jintao He,^{a,b,c} Xiaoxing Du,^{a,b,c} Xi Zeng,^{d,e} Robert A. Moran,^f Willem van Schaik,^f Quanming Zou,^d Yunsong Yu,^{a,b,c}  Jinyong Zhang,^d  Xiaoting Hua^{a,b,c}

^aDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

^bKey Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Hangzhou, Zhejiang, China

^cRegional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

^dNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China

^eDepartment of Pharmacy, The 78th Group Army Hospital of Chinese PLA, Mudanjiang, Heilongjiang, China

^fInstitute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

Jintao He, Xiaoxing Du, and Xi Zeng contributed equally to this article. Author order was determined by type of contribution.

ABSTRACT Carbapenem-resistant hypervirulent *Klebsiella pneumoniae* (CR-hvKP) is a threat to global public health. We characterized a sequence type 17 (ST17) *K. pneumoniae* clinical isolate that was resistant to carbapenems and belonged to serotype KL38/O2. Its complete genome is comprised of a 5.1-Mb chromosome and two conjugative plasmids. The 52,578-bp N-type plasmid pXH210-IMP contains the *bla*_{IMP-4} carbapenemase gene and the quinolone resistance gene *qnrS1*. The 272,742-bp FII(K)-9:FIB(K)-10 plasmid pXH210-AMV carries an array of genes that confer resistance to aminoglycosides, chloramphenicol, quinolones, tetracycline, sulfonamides, trimethoprim, arsenic, copper, and silver. However, the XH210 genome otherwise lacks the genes that are considered characteristic markers of hypervirulence in *K. pneumoniae*. The virulence potential of XH210 was assessed using a random forest algorithm predictive model, as well as *Galleria mellonella* and mouse infection models. The results of these were concordant and suggested that XH210 is hypervirulent and therefore a CR-hvKP strain. This worrying convergence of virulence and clinically significant antibiotic resistance is particularly concerning given the absence of typical hypervirulence markers. Further investigations are required to understand the virulence mechanisms of XH210 and to improve the diagnostics of hypervirulent *K. pneumoniae*.

IMPORTANCE The combination of drug resistance and hypervirulence significantly limits the available treatment options for life-threatening infections caused by multidrug-resistant hvKP, especially CR-hvKP. To date, research on IMP-producing CR-hvKP is extremely scarce, and the virulence mechanisms of CR-hvKP are far more complicated and diverse than has been described in the literature so far. In this study, we characterized the tigecycline-resistant and IMP-4 carbapenemase-producing ST17 *K. pneumoniae* isolate XH210 from a human blood sample. Importantly, XH210 exhibits hypervirulence but does not possess traits that are frequently associated with the phenotype, highlighting the urgent need to improve identification of potentially hypervirulent isolates and enhance active surveillance of CR-hvKP strains to prevent their dissemination.

KEYWORDS *Klebsiella pneumoniae*, ST17, *bla*_{IMP-4}, carbapenem resistant, hypervirulence

Klebsiella pneumoniae is a well-studied Gram-negative bacterium of the *Enterobacteriales* family and a prominent cause of community-acquired and nosocomial infections (1–3). Globally distributed antimicrobial-resistant clones, particularly carbapenem-resistant

Editor Hui Wang, Peking University People's Hospital

Copyright © 2022 He et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Xiaoting Hua, xiaotinghua@zju.edu.cn, or Jinyong Zhang, zhangjy198217@126.com.

The authors declare no conflict of interest.

Received 3 November 2021

Accepted 7 February 2022

Published 28 February 2022

TABLE 1 Genomic characteristics of *K. pneumoniae* isolate XH210

Genetic material	Replicon type	Size (bp)	GC content (%)	Antimicrobial resistance gene(s)			
				β -Lactam(s)	Aminoglycoside	Fluoroquinolone	Others
Chromosome		5,120,204	57.6	<i>bla</i> _{SHV-94r} <i>bla</i> _{SHV-96r} <i>bla</i> _{SHV-172}		<i>oqxAB</i>	<i>fosA</i>
pXH210-IMP	N	52,578	51.1	<i>bla</i> _{IMP-4}		<i>qnrS1</i>	
pXH210-AMV	FII(K)-9, FIB(K)-10	272,742	51.8	<i>bla</i> _{CTX-M-14}	<i>aacC2d</i> , <i>strAB</i>	<i>qnrS1</i>	<i>catA2</i> , <i>sul1</i> , <i>sul2</i> , <i>tet(D)</i> , <i>tet(A)</i> , <i>dfrA1</i>

K. pneumoniae (CRKP), pose serious therapeutic challenges (4). Among the *K. pneumoniae* population, hypervirulent *K. pneumoniae* (hvKP) strains exhibit increased virulence relative to classical *K. pneumoniae* (cKP) strains. Worrisomely, hvKP is becoming increasingly resistant to antibiotics through the acquisition of multiple antibiotic resistance genes, while drug-resistant cKP strains can acquire virulence genes and increase their virulence potential (5).

XH209 is a CRKP that was isolated in 2014 from the blood of a patient in Hangzhou, China, at the outset of tigecycline treatment (6). Initially, it was mistakenly believed that XH209 did not contain a carbapenemase gene or carry plasmids (7). A second isolate of the same strain, XH210, was isolated from the same patient after tigecycline treatment and shown to contain a mutation associated with tigecycline resistance (8) but has not been further characterized.

Here, we determined the complete genome sequence of *K. pneumoniae* XH210 using short- and long-read sequence data. The complete XH210 genome was characterized to assess both its antibiotic resistance and virulence potential. The transferability of multidrug resistance plasmids in XH210 was determined in the laboratory. The virulence of XH210 was assessed using the random forest algorithm predictive model and confirmed via mouse pneumonia and *Galleria mellonella* infection models.

RESULTS

Isolate characteristics. The genome of *K. pneumoniae* XH210 consists of a 5,120,204-bp chromosome and two plasmids (Table 1). XH210 belongs to sequence type 17 (ST17), its capsule type is KL38, and its O antigen type is O2. Antimicrobial susceptibility testing (AST) revealed that XH210 exhibits resistance to most tested antibiotics but is susceptible to amikacin (Table 2). The XH210 genome contains multiple antibiotic resistance genes, including ones that confer resistance to aminoglycosides (*aacC2d* and *strAB*), β -lactams (*bla*_{SHV-94r}, *bla*_{SHV-96r}, *bla*_{SHV-172r}, *bla*_{IMP-4r}, and *bla*_{CTX-M-14r}), fosfomycin (*fosA*), quinolones (*oqxAB* and *qnrS1*), phenicol (*catA2*), sulfonamides (*sul1* and *sul2*), tetracycline [*tet* (A) and *tet*(D)], and trimethoprim (*dfrA1*). *bla*_{SHV-94r}, *bla*_{SHV-96r}, *bla*_{SHV-172r}, *oqxAB*, and *fosA* are located in the XH210 chromosome. The smaller plasmid, pXH210-IMP, carries both the *qnrS1* and *bla*_{IMP-4} genes, while the remaining resistance genes are located in the larger plasmid, pXH210-AMV.

We constructed a core genome phylogenetic tree using XH210 and 17 further ST17 *K. pneumoniae* strains isolated in China, which divided into two clusters (Fig. 1). The first cluster is comprised of isolates derived from North China, some carrying carbapenemase

TABLE 2 Antimicrobial susceptibilities of *K. pneumoniae* XH210, recipient strains, and transconjugants

Strain	Annotation	MIC (μ g/mL) of ^a :							
		MEM	IPM	CHL	TET	AK	CTX	FEP	CRO
XH210	The original isolate	16	4	>256	>256	1	128	128	>128
XH1538	J53 transconjugant with pXH210-IMP	4	2	4	0.5	2	256	128	>128
XH1539	J53 transconjugant with pXH210-AMV	≤0.0625	0.25	>256	256	4	16	64	>128
XH1540	XH1541 transconjugant with pXH210-IMP and pXH210-AMV	8	4	>256	>256	0.5	32	32	64
XH1541	<i>K. pneumoniae</i> ATCC 13883-Rif ^r , rifampicin resistant	≤0.0625	0.5	4	1	0.5	≤0.25	≤0.125	≤0.125
J53	<i>E. coli</i> J53, sodium azide resistant	≤0.0625	0.125	4	1	2	≤0.25	≤0.125	≤0.125

^aMEM, meropenem; IPM, imipenem; CHL, chloramphenicol; TET, tetracycline; AK, amikacin; CTX, cefotaxime; FEP, cefepime; CRO, ceftriaxone.




FIG 1 The phylogenetic tree of ST17 isolates. Eighteen ST17 *K. pneumoniae* genome sequences were used. Information for the ST17 strains is shown on the right, including carbapenemase gene, isolation source, location, and time.

gene *bla*_{NDM-1} or *bla*_{OXA-181}. The second cluster contains isolates from West China and South China, some of which, including XH210, harbor carbapenemase gene *bla*_{IMP-4}.

Characterization of pXH210-AMV and pXH210-IMP. pXH210-AMV is a 272,742-bp F-type plasmid that contains FII(K)-9 and FIB(K)-10 replicons. Although it has been heavily modified by translocatable elements, pXH210-AMV contains a complete and uninterrupted F-like transfer region (9). The antibiotic resistance genes in pXH210-AMV confer resistance to multiple classes of antibiotics (Table 1), and the plasmid also contains genes expected to confer resistance to silver (*silABCERS*), copper (*pcoABCDRS*), and arsenic (*ars*).

pXH210-IMP is an N-type plasmid that contains *bla*_{IMP-4} and *qnrS1* in two different insertion regions (Fig. 2A). The *bla*_{IMP-4} gene is located in a group II intron-containing class 1 integron that has previously been designated In823::*Kl.pn.I3* when found in pIMP-HZ1 (GenBank accession number [KU886034](#)), the first sequenced *bla*_{IMP-4}-carrying plasmid (10). The *qnrS1* genes in pXH210-IMP and pIMP-HZ1 are found in 2,747-bp and 2,959-bp segments, respectively, between copies of IS26 and IS*Kpn19*. An IS*Kpn19*-mediated deletion is responsible for the shorter segment in pXH210-IMP. The backbones of pXH210-IMP and pIMP-HZ1 differ in the lengths of two short repeat regions associated with the equivalent to the resolvase gene of R46 and with the origin of transfer (*oriT*). pXH210-IMP contains a complete and uninterrupted R46-like transfer region that contains all determinants required for conjugative transfer. A number of plasmids from different bacterial hosts are closely related to pXH210-IMP and pIMP-HZ1 (Fig. 2B), indicating that this lineage of *bla*_{IMP-4}-harboring N-type plasmids is widely disseminated.

Both antibiotic resistance plasmids in XH210 are conjugative. To test the transferability of pXH210-IMP and pXH210-AMV, we performed conjugation experiments where XH210 was the donor and *Escherichia coli* strain J53 or *K. pneumoniae* strain XH1541 (ATCC 13883-Rif^r) was the recipient. pXH210-IMP transferred to strains J53 and XH1541 at mean frequencies of 4.7×10^{-5} and 1.3×10^{-4} transconjugants per donor cell




FIG 2 Characterization of *bla*_{IMP-4}-carrying plasmid pXH210-IMP. (A) Circular map of pXH210-IMP. AMR, antimicrobial resistance genes; IS, insertion sequence-associated genes; CT, conjugal transfer-related genes. (B) Scaled, linear sequence comparison between plasmids pXH210-IMP, pIMP-HZ1 (KU886034), pP10159-2 (MF072962), pIMP-GZ1058 (KU051709), P378-IMP (KX711879), and p13SP-IMP (MH909334). Antibiotic resistance genes are shown in red arrows. The individual conjugation-related genes are shown with dark green arrows. Blue arrows show insertion sequence-associated genes. The other genes are shown as orange arrows.

(TC/D), respectively, while pXH210-AMV transferred to J53 and XH1541 at 9.9×10^{-7} and 9.7×10^{-7} TC/D, respectively. According to S1 nuclease pulsed-field gel electrophoresis (S1-PFGE) and the corresponding Southern blot hybridizations, XH210 contains two plasmids with sizes of ~54 kb and ~270 kb, and *bla*_{IMP-4} is located in the ~54-kb plasmid, consistent with the sequence data (Fig. 3). These two plasmids were transferred separately into *E. coli* J53, while they were cotransferred into *K. pneumoniae* XH1541 using the same methods. AST showed that the *K. pneumoniae* transconjugant XH1540 exhibited resistant phenotypes similar to those of XH210, although the MICs of some agents were lower than those of the donor (Table 2). *E. coli* transconjugant XH1538, carrying pXH210-IMP, exhibited resistance to all tested β -lactams, including cefotaxime, cefepime, ceftriaxone, imipenem, and meropenem, but remained susceptible to chloramphenicol and tetracycline. In contrast, *E. coli* transconjugant XH1539, carrying pXH210-AMV, exhibited resistance to chloramphenicol and tetracycline but remained susceptible to imipenem and meropenem. This indicated that pXH210-IMP accounts for the carbapenem resistance phenotype of XH210, while pXH210-AMV accounts for the chloramphenicol and tetracycline resistance phenotypes, as predicted from the sequence data.

Comparing the virulence of *K. pneumoniae* strains ATCC 700721, NTUH-K2044, and XH210 in *G. mellonella* larvae and the mouse pneumonia model. Allelic profiles of XH210 core genes were input into the virulence prediction model of Lan et al. (11), which predicted that the isolate was hypervirulent. To confirm this, we investigated the susceptibility of *G. mellonella* larvae to *K. pneumoniae* XH210 and strain NTUH-K2044, which is used as a hypervirulent reference strain in molecular pathogenesis studies (12). *K. pneumoniae* ATCC 700721 was used as a nonhypervirulent control strain. The results showed that when larvae were injected with 1×10^5 CFU of one of the strains, identical trends were observed between the XH210 and ATCC 700721 infections, with no statistical difference ($P = 0.087$). The mortality of larvae was similar or even slightly higher for XH210 than for NTUH-K2044 (Fig. 4), indicating that XH210 exhibited a virulence level similar to that of the hvKP control strain. A mouse pneumonia model was employed to further evaluate the *in vivo* virulence of XH210. BALB/c mice were intratracheally infected with 1×10^6 , 1×10^7 , or 1×10^8 CFU of *K. pneumoniae*, and the survival rates, body weights, and clinical scores of the mice were recorded. All mice infected with XH210 or NTUH-K2044 succumbed to the infection, even when the infective dose was reduced to 1×10^6 CFU. In contrast, up to 80% of




FIG 3 S1 nuclease-digested plasmid DNA and Southern blot hybridization of XH210 and corresponding transconjugants XH210, XH1539, and XH1540 (A) and of XH1538 (B). The red arrows show positive signals via Southern blot hybridization with a *bla*_{IMP-4}-specific (for pXH210-IMP) or *catA2*-specific (for pXH210-AMV) probe.

mice inoculated with 1×10^8 CFU of ATCC 700721 survived the infection (Fig. 5A). The weight loss of mice infected with ATCC 700721 was dependent on the inoculated dose (Fig. 5B), and the clinical scores of mice that received ATCC 700721 generally recovered by day 7 (Fig. 5C). In contrast, the body weights and clinical scores of mice infected with XH210 or NTUH-K2044 declined continuously until death (Fig. 5B and C). These results suggest that, like NTUH-K2044, XH210 is a hypervirulent strain, supporting the random forest model’s prediction and the results from the *G. mellonella* model.

DISCUSSION

The emergence of hvKP that can cause severe infections with high mortality rates in apparently healthy people has raised serious concern globally (13). HvKP strains are usually susceptible to most antimicrobials apart from ampicillin, but like cKP lineages, hvKP strains have acquired resistance to multiple antimicrobial agents in recent years (14). Meanwhile, drug-resistant cKP strains have obtained hvKP-specific virulence factors (5). It has been predicted that drug-resistant cKP strains are more likely to acquire virulence genes than hvKP strains are to acquire antibiotic resistance genes (15). The combination of drug resistance and hypervirulence significantly limits the available treatment options for life-threatening infections caused by multidrug-resistant hvKP, especially carbapenem-resistant hvKP (CR-hvKP). In this study, we characterized *K. pneumoniae* isolate XH210, an ST17 CR-hvKP isolate from a human blood sample.

Although it is difficult for clinical laboratories to distinguish hvKP and cKP, serotyping and genomic background characterization can provide valuable information regarding the definition of hvKP. To date, the K1 and K2 capsular serotypes have accounted for approximately 70% of hvKp isolates (5, 7). Detection of five genotypic




FIG 4 Virulence of individual isolates in the *G. mellonella* model. Larvae were inoculated with 10^5 CFU of XH210, NTUH-K2044, or PBS. Survival was monitored every 12 h for 3 days. The experiment was repeated in biological triplicate, and the data are the mean values.

markers for a virulence plasmid (*peg-344*, *iroB*, *iucA*, *rmpA*, and *rmpA2*) coupled with detection of siderophore production showed >0.95 diagnostic accuracy for differentiating hvKP from cKP (16). However, a contrary report suggested that virulence factors (*rmpA*, *iucA*, positive string test, and pLVPK) were poor predictors for hvKP (5). A random forest model based on the core genome allelic profile showed >0.98 diagnostic accuracy for hvKP (11). *G. mellonella* larvae have been considered a consolidated *in vivo* infection model for *K. pneumoniae* (17, 18). However, Russo and MacDonald reported that while a murine infection model accurately differentiated hvKP from cKP,




FIG 5 Virulence of ATCC 700721, NTUH-K2044, and XH210 in mouse pneumonia model. Mice were infected with 10^6 , 10^7 , or 10^8 CFU of *K. pneumoniae* intratracheally, and the survival rates (A), body weights (B), and clinical scores (C) of mice were recorded for 7 days.

a *G. mellonella* model did not (19). In this study, *K. pneumoniae* XH210 was predicted to be hypervirulent using the random forest algorithm predictive model. We used *G. mellonella* and murine models to confirm the virulence of *K. pneumoniae* XH210, which belonged to KL38/O2 and did not contain any of the significant virulence factors described above. The most obvious putative virulence genes in pXH210-AMV appear to be *fecABCDER*, which encode a siderophore system for iron acquisition. However, no statistical difference was observed between J53 and XH1539 (J53 harboring pXH210-AMV) in virulence experiments (Fig. 4). We hypothesize that the hypervirulence of XH210 is determined by a variety of factors, such as a type VI secretion system (TssBCJFG), fimbrial proteins (MrkABCFHIJ), capsule biosynthesis proteins (RcsA and RcsB), and possibly *FecABCDER*, but the exact mechanisms remain unclear. Our results also confirmed the correlation between *G. mellonella* and murine infection models for virulence, but strong conclusions cannot be drawn due to the limited numbers of strains tested here. Further investigations are required to strengthen our understanding of the virulence mechanisms of XH210.

We demonstrated that both pXH210-AMV and pXH210-IMP were conjugative plasmids that could be transferred from XH210 to *E. coli* and *K. pneumoniae* recipients. pXH210-IMP is closely related to pIMP-HZ1, from a *K. pneumoniae* isolate obtained from a patient from Huizhou in 2010 (10). Both pXH210-IMP and pIMP-HZ1 could be transferred by conjugation to an *E. coli* recipient at high frequencies, but the efficiency of pXH210-IMP (4.7×10^{-5} per donor cell) was slightly lower than that of pIMP-HZ1 (1.2×10^{-4} per donor cell). This observation of a conjugative carbapenem resistance plasmid in hvKP XH210 is important, as it has been postulated that hvKP strains are less likely to acquire carbapenemase plasmids than cKP strains (15).

In conclusion, the CR-hvKP clinical isolate XH210 was characterized as ST17 KL38/O2 serotype and was hypervirulent, which was confirmed by the random forest algorithm predictive model, *G. mellonella* larva infection model, and mouse pneumonia model. XH210 exhibited resistance to most tested antibiotics but was susceptible to amikacin. Most of XH210's resistance determinants were found in two conjugative plasmids, a widely disseminated *bla*_{IMP-4}-carrying N-type plasmid and a large F-type plasmid carrying antibiotic and metal resistance genes. Importantly, XH210 exhibited hypervirulence but did not possess traits that are frequently associated with the phenotype. This suggests that further work is required to improve the identification of potentially hypervirulent isolates and that active surveillance of CR-hvKP strains should be implemented urgently.

MATERIALS AND METHODS

Whole-genome sequencing and sequence analysis. The genomic DNA of XH210 was extracted using the QIAamp DNA minikit (Qiagen, Valencia, CA) and sequenced on the HiSeq X ten (Illumina, San Diego, CA, USA) and MinION platforms (Nanopore, Oxford, UK) at Zhejiang Tianke (Hangzhou, China). The Illumina and Nanopore reads were hybrid assembled using Unicycler version 0.4.8 (20). Assembled contigs were annotated using Prokka (21). Resfinder was used to identify antimicrobial resistance genes (<https://cge.cbs.dtu.dk/services/ResFinder/>). The PlasmidFinder, pMLST, and KpVR tools were used to detect and type plasmid replicons (22). The virulence prediction model was built using a Random Forest algorithm based on core genome allelic profiles of *K. pneumoniae* strains (11).

Phylogenetic analysis. A collection of *K. pneumoniae* ST17 genomes were obtained from NCBI (Table 3). The core genome phylogeny was constructed using Roary version 3.12.0 (23). A phylogenetic tree was generated with FastTree version 2.1.10 (24), and the output graphic file was generated via ggtree (25).

Plasmid transfer experiments. Conjugation experiments were carried out by filter mating using rifampicin-resistant *K. pneumoniae* strain XH1541 and the sodium azide-resistant *E. coli* strain J53 as the recipients, as described previously (26). Transconjugants were selected using MH agar plates containing 1 $\mu\text{g}/\text{mL}$ meropenem and 300 $\mu\text{g}/\text{mL}$ sodium azide (for pXH210-IMP), 1 $\mu\text{g}/\text{mL}$ meropenem and 300 $\mu\text{g}/\text{mL}$ rifampicin (for pXH210-IMP), 100 $\mu\text{g}/\text{mL}$ chloramphenicol and 300 $\mu\text{g}/\text{mL}$ sodium azide (for pXH210-AMV), or 100 $\mu\text{g}/\text{mL}$ chloramphenicol and 300 $\mu\text{g}/\text{mL}$ rifampicin (for pXH210-AMV). Conjugation frequencies were calculated by dividing the number of transconjugants (CFU/mL) by the number of donor cells (CFU/mL). PCR analysis and MIC profiling were carried out to determine the difference between the parental strain and the corresponding transconjugants. S1-PFGE and Southern blotting were performed as described previously (27). DNA fragments were hybridized with a

TABLE 3 ST17 *K. pneumoniae* genome sequences downloaded from NCBI for comparison to XH210

Strain	Assembly accession no.	Yr	Location	Host	Isolation source	Carbapenemase
NSKp22-1	GCA_011683205.1	2020	Beijing	<i>Homo sapiens</i>	Nasopharynx	NDM-1
NSKp22-2	GCA_011683185.1	2020	Beijing	<i>Homo sapiens</i>	Nasopharynx	NDM-1
CKp22-2	GCA_011683155.1	2020	Beijing	<i>Homo sapiens</i>	Bronchoalveolar lavage fluid	NDM-1
YML0508	GCA_009884395.1	2020	China	<i>Homo sapiens</i>	Rectum	OXA-181
NJYKDXFSD EYY933-CR	GCA_006130295.1	2019	Nanjing	<i>Homo sapiens</i>	Sputum	NA ^a
F93-2	GCA_004120175.1	2019	Fujian	<i>Homo sapiens</i>	Sputum	NA
AM17-27	GCA_003471715.1	2018	Shenzhen	<i>Homo sapiens</i>	Feces	NA
WCHKP085214	GCA_003037795.1	2018	Chengdu	<i>Homo sapiens</i>	NA	NA
SKLX2821	GCA_001701615.1	2016	China	<i>Homo sapiens</i>	Sputum	NA
SKLX2467	GCA_001701585.1	2016	China	<i>Homo sapiens</i>	Sputum	NA
XH210	GCA_001699105.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4
XH216	GCA_001699095.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4
XH215	GCA_001699045.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4
XH214	GCA_001699035.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	NA
XH213	GCA_001699025.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4
XH211	GCA_001699015.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	NA
XH212	GCA_001698945.1	2016	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4
XH209	GCA_000775955.1	2014	Hangzhou	<i>Homo sapiens</i>	Blood	IMP-4

^aNA, not available.

digoxigenin-labeled *bla*_{IMP-4}-specific or *catA2*-specific probe. *Salmonella enterica* serotype Braenderup H9812 digested with XbaI was used as a size marker.

Antimicrobial susceptibility testing. The original strain XH210, the recipient strains *E. coli* J53 and XH1541, and transconjugants were tested for their susceptibility to imipenem, meropenem, chloramphenicol, tetracycline, amikacin, cefotaxime, cefepime, and ceftriaxone by the broth microdilution method according to the guidelines provided by the Clinical and Laboratory Standards Institute (28). The *E. coli* strain ATCC 25922 was used for quality control.

Galleria mellonella infection model. The survival of *G. mellonella* larvae was assayed as previously described (29). Log-phase cell cultures were centrifuged and resuspended in phosphate-buffered saline (PBS) to 10⁷ CFU/mL. Ten larvae were injected with 10 μ L of bacterial suspension and incubated at 37°C in darkness. Ten microliters of PBS was injected in parallel as a control group. Viability was assessed by checking for movement every 12 h, and the dead larvae were counted for 3 days. The experiment was repeated in biological triplicate.

Virulence evaluation in mouse pneumonia model. Six- to 8-week-old female BALB/c mice that weighed 18 to 22 g were purchased from Hunan SLAC Jingda Laboratory Animal Co. Ltd. (Hunan, China) and kept under specific-pathogen-free conditions. All mouse experiments were approved by the Animal Ethical and Experimental Committee of Third Military Medical University. Five mice were included in each group. Intraperitoneal injection of pentobarbital sodium (75 mg/kg of body weight) was used to anesthetize the mice, and *K. pneumoniae* diluted in 20 μ L PBS was inoculated intratracheally (30). The actual concentrations of inoculated bacteria were determined by plating serial dilutions on LB agar plates. The survival rates, body weights, and clinical scores of mice were continuously observed and recorded for 7 days after infection. The evaluation standard for clinical scores was assessed as described previously (31). The experiment was repeated in biological triplicate. The log-rank test for survival rate and Student's *t* test for body weight and clinical score were performed using GraphPad Prism 6.

Data availability. The complete genome sequences of the *K. pneumoniae* XH210 isolate were deposited in GenBank under accession numbers CP052761 to CP052763.

ACKNOWLEDGMENTS

This work was supported by a grant from the National Natural Science Foundation of China (grant number 81830069). R.A.M. and W.v.S. were supported by the NSFC-MRC DETECTIVE project (grant number MR/S013660/1).

We declare no competing interests.

REFERENCES

- Bengoechea JA, Sa Pessoa J. 2019. Klebsiella pneumoniae infection biology: living to counteract host defences. *FEMS Microbiol Rev* 43:123–144. <https://doi.org/10.1093/femsre/fuy043>.
- Broberg CA, Palacios M, Miller VL. 2014. Klebsiella: a long way to go towards understanding this enigmatic jet-setter. *F1000Prime Rep* 6:64. <https://doi.org/10.12703/P6-64>.
- Wang TC, Lin JC, Chang JC, Hiaso YW, Wang CH, Chiu SK, Fung CP, Chang FY, Siu LK. 2021. Virulence among different types of hypervirulent Klebsiella pneumoniae with multi-locus sequence type (MLST)-11, serotype K1 or K2 strains. *Gut Pathog* 13:40. <https://doi.org/10.1186/s13099-021-00439-z>.
- Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC Comparative Sequencing Program Group, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. *Sci Transl Med* 4:148ra116. <https://doi.org/10.1126/scitranslmed.3004129>.

5. Russo TA, Marr CM. 2019. Hypervirulent *Klebsiella pneumoniae*. Clin Microbiol Rev 32:e00001-19. <https://doi.org/10.1128/CMR.00001-19>.
6. Hua X, Chen Q, Li X, Feng Y, Ruan Z, Yu Y. 2014. Complete genome sequence of *Klebsiella pneumoniae* sequence type 17, a multidrug-resistant strain isolated during tigecycline treatment. Genome Announc 2:e01337-14. <https://doi.org/10.1128/genomeA.01337-14>.
7. Liu Y, Long D, Xiang TX, Du FL, Wei DD, Wan LG, Deng Q, Cao XW, Zhang W. 2019. Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing *Klebsiella pneumoniae* of capsular serotype K2 and ST86. J Antimicrob Chemother 74:1233–1240. <https://doi.org/10.1093/jac/dkz023>.
8. Fang L, Chen Q, Shi K, Li X, Shi Q, He F, Zhou J, Yu Y, Hua X. 2016. Step-wise increase in tigecycline resistance in *Klebsiella pneumoniae* associated with mutations in *ramR*, *lon* and *rpsJ*. PLoS One 11:e0165019. <https://doi.org/10.1371/journal.pone.0165019>.
9. Moran RA, Hall RM. 2018. Evolution of regions containing antibiotic resistance genes in FII-2-FIB-1 ColV-Colla virulence plasmids. Microb Drug Resist 24:411–421. <https://doi.org/10.1089/mdr.2017.0177>.
10. Lo WU, Cheung YY, Lai E, Lung D, Que TL, Ho PL. 2013. Complete sequence of an IncN plasmid, pIMP-HZ1, carrying blaIMP-4 in a *Klebsiella pneumoniae* strain associated with medical travel to China. Antimicrob Agents Chemother 57:1561–1562. <https://doi.org/10.1128/AAC.02298-12>.
11. Lan P, Shi Q, Zhang P, Chen Y, Yan R, Hua X, Jiang Y, Zhou J, Yu Y. 2020. Core genome allelic profiles of clinical *Klebsiella pneumoniae* strains using a random forest algorithm based on multilocus sequence typing scheme for hypervirulence analysis. J Infect Dis 221:S263–S271. <https://doi.org/10.1093/infdis/jiz562>.
12. Insua JL, Llobet E, Moranta D, Perez-Gutierrez C, Tomas A, Garmendia J, Bengoechea JA. 2013. Modeling *Klebsiella pneumoniae* pathogenesis by infection of the wax moth *Galleria mellonella*. Infect Immun 81:3552–3565. <https://doi.org/10.1128/IAI.00391-13>.
13. Feng Y, Lu Y, Yao Z, Zong Z. 2018. Carbapenem-resistant hypervirulent *Klebsiella pneumoniae* of sequence type 36. Antimicrob Agents Chemother 62:e02644-17. <https://doi.org/10.1128/AAC.02644-17>.
14. Zhang Y, Zeng J, Liu W, Zhao F, Hu Z, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Li S, Cao B, Wang H. 2015. Emergence of a hypervirulent carbapenem-resistant *Klebsiella pneumoniae* isolate from clinical infections in China. J Infect 71:553–560. <https://doi.org/10.1016/j.jinf.2015.07.010>.
15. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, Lam MMC, Duchene S, Jenney A, Holt KE. 2019. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of *Klebsiella pneumoniae*. PLoS Genet 15:e1008114. <https://doi.org/10.1371/journal.pgen.1008114>.
16. Russo TA, Olson R, Fang CT, Stoesser N, Miller M, MacDonald U, Hutson A, Barker JH, La Hoz RM, Johnson JR. 2018. Identification of biomarkers for differentiation of hypervirulent *Klebsiella pneumoniae* from classical *K. pneumoniae*. J Clin Microbiol 56:e00776-18. <https://doi.org/10.1128/JCM.00776-18>.
17. Cutuli MA, Petronio Petronio G, Vergalito F, Magnifico I, Pietrangelo L, Venditti N, Di Marco R. 2019. *Galleria mellonella* as a consolidated in vivo model hosts: new developments in antibacterial strategies and novel drug testing. Virulence 10:527–541. <https://doi.org/10.1080/21505594.2019.1621649>.
18. Jiang L, Greene MK, Insua JL, Pessoa JS, Small DM, Smyth P, McCann AP, Cogo F, Bengoechea JA, Taggart CC, Scott CJ. 2018. Clearance of intracellular *Klebsiella pneumoniae* infection using gentamicin-loaded nanoparticles. J Control Release 279:316–325. <https://doi.org/10.1016/j.jconrel.2018.04.040>.
19. Russo TA, MacDonald U. 2020. The *Galleria mellonella* infection model does not accurately differentiate between hypervirulent and classical *Klebsiella pneumoniae*. mSphere 5:e00850-19. <https://doi.org/10.1128/mSphere.00850-19>.
20. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. <https://doi.org/10.1371/journal.pcbi.1005595>.
21. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
22. Tian D, Wang M, Zhou Y, Hu D, Ou HY, Jiang X. 2021. Genetic diversity and evolution of the virulence plasmids encoding aerobactin and salmochelin in *Klebsiella pneumoniae*. Virulence 12:1323–1333. <https://doi.org/10.1080/21505594.2021.1924019>.
23. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics 31:3691–3693. <https://doi.org/10.1093/bioinformatics/btv421>.
24. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One 5:e9490. <https://doi.org/10.1371/journal.pone.0009490>.
25. Yu G, Lam TT, Zhu H, Guan Y. 2018. Two methods for mapping and visualizing associated data on phylogeny using Ggtree. Mol Biol Evol 35:3041–3043. <https://doi.org/10.1093/molbev/msy194>.
26. Fan J, Zhang L, He J, Zhao M, Loh B, Leptihn S, Yu Y, Hua X. 2020. Plasmid dynamics of *mcr-1*-positive *Salmonella* spp. in a general hospital in China. Front Microbiol 11:604710. <https://doi.org/10.3389/fmicb.2020.604710>.
27. Quan J, Li X, Chen Y, Jiang Y, Zhou Z, Zhang H, Sun L, Ruan Z, Feng Y, Akova M, Yu Y. 2017. Prevalence of *mcr-1* in *Escherichia coli* and *Klebsiella pneumoniae* recovered from bloodstream infections in China: a multi-centre longitudinal study. Lancet Infect Dis 17:400–410. [https://doi.org/10.1016/S1473-3099\(16\)30528-X](https://doi.org/10.1016/S1473-3099(16)30528-X).
28. CLSI. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Xu Q, Chen T, Yan B, Zhang L, Pi B, Yang Y, Zhang L, Zhou Z, Ji S, Leptihn S, Akova M, Yu Y, Hua X. 2019. Dual role of *gnaA* in antibiotic resistance and virulence in *Acinetobacter baumannii*. Antimicrob Agents Chemother 63:e00694-19. <https://doi.org/10.1128/AAC.00694-19>.
30. Rodriguez-Hernandez MJ, Pachon J, Pichardo C, Cuberos L, Ibanez-Martinez J, Garcia-Curiel A, Caballero FJ, Moreno I, Jimenez-Mejias ME. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in *Acinetobacter baumannii* experimental pneumonia. J Antimicrob Chemother 45:493–501. <https://doi.org/10.1093/jac/45.4.493>.
31. Du X, Xue J, Jiang M, Lin S, Huang Y, Deng K, Shu L, Xu H, Li Z, Yao J, Chen S, Shen Z, Feng G. 2021. A multipeptide peptide, rOmp22, encapsulated in chitosan-PLGA nanoparticles as a candidate vaccine against *Acinetobacter baumannii* infection. Int J Nanomedicine 16:1819–1836. <https://doi.org/10.2147/IJN.S296527>.